BACKGROUND: Detecting early-stage Alzheimer's disease in clinical practice is difficult due to a lack of efficient and easily administered cognitive assessments that are sensitive to very mild impairment, a likely contributor to the high rate of unde...
BACKGROUND: Many neurocognitive and neuropsychological tests are used to classify early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and Alzheimer's disease (AD) from cognitive normal (CN). This can make it challenging for...
BACKGROUND: Amyloid-β (Aβ) evaluation in amnestic mild cognitive impairment (aMCI) patients is important for predicting conversion to Alzheimer's disease. However, Aβ evaluation through Aβ positron emission tomography (PET) is limited due to high cos...
Studies in health technology and informatics
Jun 16, 2020
The disease multiple sclerosis (MS) is characterized by various neurological symptoms. This paper deals with a novel tool to assess cognitive dysfunction. The Brief Visuospatial Memory Test-Revised (BVMT-R) is a recognized method to measure optical r...
OBJECTIVES: To use a Machine Learning (ML) approach to compare Neuropsychiatric Symptoms (NPS) in participants of a longitudinal study who developed dementia and those who did not.
BACKGROUND: The widespread incidence and prevalence of Alzheimer's disease and mild cognitive impairment (MCI) has prompted an urgent call for research to validate early detection cognitive screening and assessment.
American journal of Alzheimer's disease and other dementias
Jan 1, 2020
BACKGROUND: The mobile screening test system for mild cognitive impairment (mSTS-MCI) was developed and validated to address the low sensitivity and specificity of the Montreal Cognitive Assessment (MoCA) widely used clinically.
BACKGROUND: Several studies investigated clinical and instrumental differences to make diagnosis of dementia in general and in Alzheimer's disease (AD) in particular with the aim to classify, at the individual level, AD patients and healthy controls ...
BACKGROUND: Machine learning (ML) is a promising technique for patient-specific prediction of mild cognitive impairment (MCI) and dementia development. Neuropsychiatric symptoms (NPS) might improve the accuracy of ML models but have barely been used ...
BACKGROUND: Amyloid-β positivity (Aβ+) based on PET imaging is part of the enrollment criteria for many of the clinical trials of Alzheimer's disease (AD), particularly in trials for amyloid-targeted therapy. Predicting Aβ positivity prior to PET ima...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.